BIOMAT Database Logo BIOMAT Database Logo

The use of gemfibrozil in the treatment of primary hyperlipoproteinaemia. Preliminary report. 1976

J Honorato, and R M Masso, and A Purroy

UI MeSH Term Description Entries
D006949 Hyperlipidemias Conditions with excess LIPIDS in the blood. Hyperlipemia,Hyperlipidemia,Lipemia,Lipidemia,Hyperlipemias,Lipemias,Lipidemias
D008074 Lipoproteins Lipid-protein complexes involved in the transportation and metabolism of lipids in the body. They are spherical particles consisting of a hydrophobic core of TRIGLYCERIDES and CHOLESTEROL ESTERS surrounded by a layer of hydrophilic free CHOLESTEROL; PHOSPHOLIPIDS; and APOLIPOPROTEINS. Lipoproteins are classified by their varying buoyant density and sizes. Circulating Lipoproteins,Lipoprotein,Lipoproteins, Circulating
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001835 Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms. Body Weights,Weight, Body,Weights, Body
D002784 Cholesterol The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils. Epicholesterol
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

J Honorato, and R M Masso, and A Purroy
The treatment of hyperlipoproteinaemia with gemfibrozil compared with placebo and clofibrate.
November 1980, The New Zealand medical journal,
J Honorato, and R M Masso, and A Purroy
Gemfibrozil in the treatment of resistant familial hypercholesterolaemia and type III hyperlipoproteinaemia.
May 1988, Journal of the Royal Society of Medicine,
J Honorato, and R M Masso, and A Purroy
Evaluation of increasing doses of gemfibrozil in hyperlipoproteinaemia.
January 1976, Proceedings of the Royal Society of Medicine,
J Honorato, and R M Masso, and A Purroy
Effect of gemfibrozil on lipoprotein concentrations in different types of hyperlipoproteinaemia.
January 1976, Proceedings of the Royal Society of Medicine,
J Honorato, and R M Masso, and A Purroy
Therapeutic effects of bezafibrate and gemfibrozil in hyperlipoproteinaemia type IIa and IIb.
January 1989, Current medical research and opinion,
J Honorato, and R M Masso, and A Purroy
Ciprofibrate versus gemfibrozil in the treatment of primary hyperlipidaemia.
July 1996, Atherosclerosis,
J Honorato, and R M Masso, and A Purroy
Effect of gemfibrozil upon platelet function and blood coagulation. Preliminary report.
January 1976, Proceedings of the Royal Society of Medicine,
J Honorato, and R M Masso, and A Purroy
[Classification of hyperlipoproteinaemia in primary gout].
April 1972, Deutsche medizinische Wochenschrift (1946),
J Honorato, and R M Masso, and A Purroy
Gemfibrozil as a lipid lowering compound in hyperlipoproteinaemia. A placebo-controlled cross-over trial.
January 1976, Proceedings of the Royal Society of Medicine,
J Honorato, and R M Masso, and A Purroy
[Simvor in the treatment of hyperlipoproteinaemia].
October 2002, Vnitrni lekarstvi,
Copied contents to your clipboard!